ããé¢æçå¤çåï¼æ¿å»çµéï¼é
¸æ´åä¼è£ï¼å 为é
¸æ´å¯å å§
æ°¢èï¼ä»è导è´æ´æå¼å¼æãå¨é¤éåæ°§åç®æ¶ï¼å°½ééç¨å·ç æ丸çæ¹æ³ï¼è¥
æ´æ°ç¡¬åº¦çäºæ大äºHRC 32çç´§åºä»¶è¿è¡é
¸æ´æ¶ï¼å¿
é¡»å¨å¶å®é
¸æ´å·¥èºæ¶ç¡®ä¿é¶ä»¶å¨é
¸ä¸æµ¸æ³¡çæ¶é´æé¿ä¸è¶
è¿10åéã并åºå°½ééä½é
¸æ¶²çæµåº¦ï¼å¹¶ä¿è¯é¶ä»¶å¨é
¸ä¸æµ¸æ³¡çæ¶é´ä¸è¶
è¿10åéã
ããé
¸æ´ï¼å©ç¨é
¸æº¶æ¶²å»é¤é¢é表é¢ä¸çæ°§åç®åéèç©çæ¹æ³ç§°ä¸ºé
¸æ´ãæ¯æ¸
æ´éå±è¡¨é¢çä¸ç§æ¹æ³ãé常ä¸é¢èï¼pre-passiviting treatmentï¼ä¸èµ·è¿è¡ã
ããä¸è¬å°å¶ä»¶æµ¸å
¥ç¡«é
¸çç水溶液ï¼ä»¥é¤å»éå±è¡¨é¢çæ°§åç©çèèãæ¯çµéã
æªç·ã轧å¶çå·¥èºçåå¤çæä¸é´å¤çã